The abstract is read at the publisher; the summary is JClub's.
On-demand TACE plus atezolizumab and bevacizumab improved investigator-assessed TACE-PFS to 11·30 months versus 7·03 months with on-demand TACE alone in unresectable intermediate-to-high HCC.
- Why it matters: Standard TACE offers limited survival benefits, so this trial tested whether adding systemic therapy could extend time to untreatable progression or TACE failure in patients without prior systemic treatment.
- What they did: In a phase 3, open-label 1:1 randomised study at 40 centres in China and Japan, 342 eligible patients received on-demand TACE plus atezolizumab 1200 mg and bevacizumab 15 mg/kg every 3 weeks (starting 14 days–8 weeks after TACE) or on-demand TACE alone; primary endpoints were TACE-PFS and overall survival.
- The result: At data cutoff (median follow-up 26·25 months), TACE-PFS was longer with combination therapy (HR 0·71, two-sided stratified log-rank p=0·0089), while overall survival remained immature and safety showed no new signals.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.